Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD

Abstract

Objective: This study aims to examine the efficacy of atomoxetine in treating symptoms of attention deficit hyperactivity disorder (ADHD) in children with severe autistic disorder. Method: Children with severe autistic disorder who had symptoms of ADHD were given atomoxetine for 10 weeks. The efficacy of atomoxetine was evaluated by using the Aberrant Behavior Checklist (ABC) to rate ADHD symptoms at baseline, week 6, and week 10. The Clinical Global Impression-Improvement (CGI-I) scale was used as secondary outcome to assess the overall improvement of the children’s development at week 10. Results: A total of 12 children participated in this study. Although CGI-I scores showed improvement at week 10, the ABC hyperactivity subscale did not show a significant improvement of the ADHD symptoms at baseline (M = 33.89) compared to those at week 10 (M = 31.78, p = .62). Conclusion: Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.

Keywords

atomoxetine autistic hyperactivity attention

Get full access to this article

View all access options for this article.

References

Aman

M. G.

Buican

Arnold

L. E.

(2003). Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 29-40.

Aman

M. G.

Singh

N. N.

Stewart

A. W.

Field

C. J.

(1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorder (4th ed., text rev.). Washington, DC: Author.

Arnold

L. E.

Aman

M. G.

Cook

A. M.

Witwer

A. N.

Hall

K. L.

Thompson

Ramadan

(2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 10.

Biederman

Heiligenstein

J. H.

Faries

D. E.

Galil

Dittmann

Emslie

G. J.

. . . Atomoxetine ADHD Study Group. (2002). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics, 110, e75.

Buitelaar

J. K.

Danckaerts

Gillberg

Zuddas

Becker

Bouvard

. . . Michelson

(2004). A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. European Child & Adolescent Psychiatry, 13, 249-257.

Cheng

Chen

(2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents—Meta-analysis and meta-regression analysis. Psychopharmacology, 194, 197-209.

Eaves

Milner

(1993). The criterion-related validity of the Childhood Autism Rating Scale and the Autism Behavior Checklist. Journal of Abnormal Child Psychology, 21, 481-491.

Escobar

Soutullo

San Sebastian

Ferneandez

Julian

Lahortiga

(2005). Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): Initial phase of 10-week treatment in a relapse prevention study with a Spanish sample. Actas Españolas de Psiquiatría, 33, 26-32.

10.

Goldstein

Schwebach

A. J.

(2004). The co-morbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: Results of a retrospective chart review. Journal of Autism and Developmental Disorders, 34, 329-339.

11.

Handen

B. L.

Johnson

C. R.

Lubetsky

(2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255.

12.

Kelsey

D. K.

Sumner

C. R.

Casat

C. D.

Coury

D. L.

Quintana

Saylor

K. E.

. . . Allen

A. J.

(2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blinded, placebo-controlled trial. Pediatrics, 114, e1-8.

13.

Lecavalier

(2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101-1114.

14.

Magyar

Pandolfi

(2007). Factor structure evaluation of the Childhood Autism Rating Scale. Journal of Autism and Developmental Disorders, 37, 1787-1794.

15.

Michelson

Faries

Wernicke

Kelsey

Kendrick

Sallee

F. R.

Spencer

(2001). Atomoxetine study group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized placebo-controlled, dose-response study. Pediatrics, 108, e83.

16.

Michelson

Allen

A. J.

Busner

Casat

Dunn

Kratochvl

. . . . West

(2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1900.

17.

Michelson

Buitelaar

J. K.

Danckaerts

Gillberg

Spencer

T. J.

Zuddar

. . . . Biederman

(2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized double-blinded, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 896-940.

18.

Posey

D. J.

Wiegand

R. E.

Wilkerson

Maynard

Stigler

K. A.

McDougle

C. J.

(2006). Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16, 599-610.

19.

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorder with hyperactivity. Archives of General Psychiatry, 62, 1266-1274.

20.

Saemundsen

Magnusson

Smari

Sigurdardottiri

(2003). Autism Diagnostic Interview-Revised and the Childhood Autism Rating Scale: Convergence and discrepancy in diagnosing autism. Journal of Autism and Developmental Disorders, 33, 319.

21.

Sinzig

Walter

Doepfner

(2009). Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: Symptoms or syndrome? Journal of Attention Disorders, 13, 117-126.

22.

Spencer

T. J.

Biederman

Wilens

T. E.

Faraone

S. V.

(2002). Overview and neurobiology of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 26, 3-9.

23.

Teal

Wiebe

. (1986) A validity analysis of selected instruments used to assess autism. J Autism Dev Disord. 16(4):485-94.

24.

Troost

P. W.

Steenhuis

M.-P.

Tuynman-Qua

H. G.

Kalverdijk

L. J.

Buitelaar

J. K.

Minderaa

R. B.

Hoekstra

P. J.

(2006). Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. Journal of Child and Adolescent Psychopharmacology, 16, 611-619.